DC MEDICAL

MEDICAL DEVICE

COMMERCIALISATION PLATFORM

WE ENVISION

BETTER LIVES

WHAT IS
DC MEDICAL

DC Medical stands for Develop & Commercialise Medical Device. DC Medical, established in 2018, introduced the a unique NRDO (No Research Develop Only) model of medical devices for the first time in Korea. We select innovative patented technologies that can enter the global medical device market, transfer them to Korea, and commercialize them. While obtaining the patented techologies, developed from the NHS (National Health Service) in the UK, we have also formed a global clinical advisory committee composed of professors and researchers in the field. We invest in post R&D, manufacturing facilities and proceed with global licensing to complete the commercialization stage in Korea. DC Medical’s Technology Commercialization Platform serves as a core element of the value chain. After acquiring CE and FDA licenses to enter the global market, we secure fast global market share. Based on the agreement with NHS, we establish business strategies with the global top 10 medical device companies. DC Medical brings innovative medical devices to the global market with a mission to save people and improve life.

PRODUCT.

Symimetic.

Biomimetic mesh for SUI & Hernia

Stress Urinary Incontinence(SUI), Pelvic Organ Prolapse(POP), and Hernia surgeries use polypropylene mesh. This product has been used continuously because it was the only solution, despite the complications; pain, inflammation, bleeding and even death. As a result, more than 150,000 lawsuits have been filed worldwide and the FDA has issued an 'BlackBox Warning'; banning the use in some areas. DC Medical licensed a technology patent that has been studied for over 7 years to replace the existing Polypropylene Mesh. Preclinical studies on animals have demonstrated that our Biomimetic Product, which has a structure similar to human tissue, reduces the likelihood of chronic pain and inflammation caused by the existing product. Symimetic will be used for SUI, pelvic effusion (POP) and hernia surgery, and the outlook is promising given that these markets are worth more than $ 5 trillion annually. Our first goal is to commercialize Biomimetic Sling products for SUI surgery.
Biomimetic Mesh
DC Medical Product
Preterm birth is a major worldwide issue. Preterm birth brings a variety of complications (about 1.1 million newborns die each year due to preterm birth) and more than 10% of pretem newborns are at risk of permanent physical disability, including cerebral palsy and hearing impairment. Diagnosis tools for Preterm birth is essential because problems caused by preterm birth can be prevented if diagnosed. However, the current technique (transvaginal ultrasound) is only applicable to a limited group of pregnant women with preterm birth history; which still shows low accuracy. EveryBaby can diagnose a preterm birth so that appropriate treatment is applicable. EveryBaby is a patented handheld devices, and its diagnostic method and procedure is much easier than with transvaginal ultrasound. Based on Electrical Impedance Spectroscopy technology, it accuratly measure the tissue's complex impedivity on the cellular structure of the tissue, and the clinical trial of 365 women shows the diagnostic accuracy to pass the UK NICE guidelines. EveryBaby is safe, has no risk to the mother and the fetus, and also has a cheap diagnostic fee. EveryBaby can be used as a routine tests for pregnant women as the accuracy for all mothers pass the UK NICE guidelines. EveryBaby is a present for every Family.
Preterm Diagnosis Device
DC Medical Product

EveryBaby.

Premature Birth Diagnostic Kit

Cryofix.

Ablation Catheter for Atrial Fibrillation

CyroFix is designed to provide an IDEAL surgery method for “Atrial Fibrillation” (AF) treatment, which 1.5% of the world's population suffer with. Atrial fibrillation is a condition in which the heart beats randomly due to abnormal electrical stimulation in the atria. Stroke, dizziness, palpitations, respiratory failure, and even depression are a few complications due to AF. The most commonly used surgery is hot/cold Ablation, in areas of the heart where abnormal electrical stimulation occurs. For at least 200 points, 15 seconds per point need to be ablated in a beating heart. Surgery has been constantly questioned for its low efficiency. Cryofix is ​​the best solution to this problem. Cryofix is ​​a catheter that introduces an innovative method of 'cryofreezing' the catheter tip to the heart temporarily and effectively. The procedure is as follows: a Cryofreezing point on the tip of a linear catheter is attached to the inner wall of the heart, then the catheter is pushed outwards, last linear ablation is performed. Linear ablation is more accurate and faster then the current point by point abliation.
Atrial Fibrillation Catheter
DC Medical Product
Trend in the organ transplant market is growing rapidly from year to year (based on OPTN statistics). However, the supply of organs is far short of demand, and the main cause can be found in organ transplant systems. The organ transplant system consists of four stages 1. Extraction, 2. Donor-recipient matching, 3. Organ transfer, and 4. Transplant surgery. The Donor-recipient matching can take upto 8 hours, leading to 'TROWING AWAY' organs because of organ failure. Todays products UW and HTK, have a short preservation time compared to OPSL, as well as better organ efficacy. Furthermore, OPSL production costs are 30% cheaper than that of the products today. OPSL's first product LS-A, is a novel solution for the preservation of abdominal organs and stores the organ in optimal condition, it is the first innovative cold storage soution in decades and will improve clinical outcomes.
Organ Preservation Solution
DC Medical Product

OPSL.

Organ Preservation Solution

TEAM.

DEVELOP & COMMERCIALISE INNOVATIVE MEDICAL TECHNOLOGY

Dabriel Choi

CHIEF
EXECUTIVE
OFFICER

C Level

Dr. Chris Winter

CHIEF
INFORMATION
OFFICER

Joohyuk Koh

Chief
Financial
Officer

J. H.

Chief
Operating
Officer

VP

Hyunjong Song

VP of
Business
Development

Kyungyoon Kang

VP OF
REGULATORY
AFFAIR

Hyung Joon Kim

VP OF
MANUFACTURING

Operations Team

David Park

Operations
Manager

Eamon
Byrne

EveryBaby
Project Manager

Mal
Jarmolowicz

OPSL
Project Manager

Sabiniano
Romano

Symimetic
Project Manager

Dr. J.H.

CryoFix
Project Manager

CAB

Dr. Christopher
Chapple

SYMIMETIC
Product
Inventor

Professor
Sheila MacNeil

Symimetic
Product
Inventor

Dr. Dilly
Anumba

Everybaby
Inventor

Prof. Peter
Lodge

OPSL
Inventor

Dr. Guy
Haywood

CryoFix
Inventor

INVESTOR.

History.

2018 08

DC Medical Established

2018 11

Angel Investment
Attracted 560 million won

2019 01

Pre-Seed Investment
Attracted 450 million won

2019 12

OPSL
Pipeline Acquisition
(IP & Researchers)

2020 01

EveryBaby
Pipeline Acquisition
(IP & Researchers)

2020 05

OPSL Domestic License
Priority Negotiation Right

2018 09

Symimetic

Pipeline Acquisition
(IP & Researchers)

2018 12

Hernia registered IP rights

2019 12

Cryofix

Pipeline Acquisition
(IP & Researchers)

2020 01

Venture Company Certified

2020 02

EveryBaby selected as Dubai Government Project

(Dubai Future Foundation)
and Collaboration with the Dubai Ministry of Health

2020 07

Government R&D Project

(Scale: 500 million won)

CONTACT.

Korean Office
PHONE: +82 2 6205 4643
EMAIL: info@dcmedical.co.kr
ADDRESS:

5F, J-TOWER B/D,139 Dosan-Daero, Gangnam-Gu, Seoul, Korea


BY CAR

There is an excellent parking lot available at J-TOWER.


BY SUBWAY

The J-TOWER office is close to the Sinsa (Line 3) stop on the Subway. From the Subway, exit 8 onto Dosan-Daero Road.
MON-FRI 09:00 - 18:00
Close Menu

Dabriel Choi

CEO 
(CHIEF EXECUTIVE OFFICER)

  • [CEO] Operates six companies including Forence Group and StickyCath
  • [Startups] Y-Accelerator Founder [In UK]
  • [Corporate Finance] Attracted investment of Series A, B including Monese [More than 30 billion won]
  • BA, University of the Arts London

CHRIS WINTER

CIO
  • Current, Brightstar Partners, Managing Partner
  • Former CTO, British Telecom
  • Former Chairman, Health Enterprise East (NHS)
  • Exit more than 10 spin-out companies [Exit 5 companies with minimum of 100 billion won]
  • Brightstar [Exit value 100 billion ]
  • Liquavista [Exit value 80 billion won]
  • Ph.D. in Physics, Lancaster University
  • Bachelor of Biochemistry, Oxford UniversityLancaster University

Joohyuk Koh

CFO 
(CHIEF FINANCIAL OFFICER)
 
  • Current HYUN, Managing Partner
  • Former Pacific Asset Management, Team Head
  • UTC Sale Advisory
  • Mirae Asset Financial Group, Management Investment Advisory
  • MSc in Taxation, Seoul National University
  • BA, Hankuk University of Foreign Studies

J. H.

Chief Operating Officer

  • More than 21 years of experience in the MedTech industry
  • 19 patents in medical device field
  • Expert in Cardiac Electrophysiology and Urology Industry
  • Certified Cardiac Electrophysiology Specialist (IBHRE)
  • BS in Mechanical Engineering

  • MBA (Master of Business Administration)

Hyunjong Song

VP OF
BUSINESS DEVELOPMENT
 
  • SOPA, Founder
  • Medi Research, Founder
  • (주)엔여기, Co-Founder
  • Ph.D., Applied Eastern Medicine, Kyung Hee University
  • Sangji University Bachelor’s and Master’s

Kyungyoon Kang

VP OF 
REGULATORY AFFAIR
 
  • Current, Head of Licensing at Cardinal Health
  • Former, Head of Licensing Department at Jude Medical
  • Former, Licensing Team Manager at Cook Inc.
  • Overall FDA approval process for more than 300 products [510K, PMA, etc.]
  • Master, Indiana University, Kelley School of Business
  • Bachelor, Indiana University

Hyung Joon Kim

VP OF 
MANUFACTURING​
 
  • Current Sambo, COO, manufacturer operation and management
  • 40 billion won in sales and 100 employees
  • General Manager of Sambo Medical Division [Production of medical devices and medical materials]
  • Bachelor, Babson College

David Park

Operations Manager

  • HW and SW project operation for 10 years

  • Expert in Operations Management

Eamon Byrne

EveryBaby Project Manager

  • 3 years engineering experience

  • Master’s Degree in Electrical and Electronics Engineering

  • MBA (Business School) Degree

Mal Jarmolowicz

OPSL Project Manager

  • Medical Technology Management at MedTech, RegenMed, Pharma

  • Experts in early stage technology development

Sabiniano Romano

Symimetic Project Manager

  • Biotransformation suitable product research and development

  • More than 7 years of research experience since the early invention

Dr. J. H.

CryoFix Project Manager

  • 5 patents related to Cardiac Ablation technology

  • Development of Cardiac Ablation System using Heat and Electricity in Medtronic

  • Ph.D. in Biomedical Engineering

Dr. ChrisTOPHER Chapple

Symimetic Product Inventor
 
  • Current, President of the European Urology Association (EAU)
  • Current, Advisor of Sheffield Teaching Hospital
  • Current, Professor of Sheffield Hallam University
  • Current, Honorary Professor of University of Sheffield
  • Current, Coordinator of European Reference Network
  • Current, Advisor of MHRA
  • Former Guidelines Development Committee of NICE
  • Middlesex University School of Medicine
  • University College London 

Professor Sheila MacNeil

Symimetic Product Inventor
 
  • Current, Professor of Tissue Engineering, University of Sheffield
  • Former Professor of Tissue Engineering, Northern General Hospital Trust
  • Former Director of the Kidney Research Foundation
  • Former CellTran R & D Director, Sheffield University Spinout Company
  • Former Meadowbank Medical Engineering Technology Consulting Director
  • Authored over 300 papers in tissue engineering
  • Ph.D., University of Sheffield
  • Bachelor, University of Aberdeen

Dr. Dilly Anumba

Everybaby Inventor
 
  • Current, Advisors Doctors and Professors at University of Sheffield Gynecology
  • Current, Vice President, Royal College of Obstetricians and Gynaecologists (RCOG)
  • Author of over 20 papers in preterm birth and fetal development
  • Ph.D., University of Newcastle-upon-Tyne
  • Medicine, University of Benin

Prof. Peter Lodge

OPSL Inventor

Dr. Guy Haywood

CryoFix Inventor